Filing Details
- Accession Number:
- 0001171843-14-004355
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-09-15 18:55:11
- Reporting Period:
- 2014-09-11
- Filing Date:
- 2014-09-15
- Accepted Time:
- 2014-09-15 17:55:11
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 3116 | Akorn Inc | AKRX | Pharmaceutical Preparations (2834) | 720717400 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1234712 | Joseph Bonaccorsi | 1925 West Field Court Suite 300 Lake Forest IL 60045 | Secretary | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2014-09-11 | 250,000 | $0.81 | 427,474 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2014-09-11 | 116,800 | $37.89 | 310,674 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Options (Right to Buy) | Disposition | 2014-09-11 | 250,000 | $0.00 | 250,000 | $0.81 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2009-05-06 | 2019-05-06 | No | 4 | M | Direct |
Footnotes
- Proceeds from the sale were used to pay exercise price and taxes due upon exercise of options.
- Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $37.81 to $38.02 per share. The reporting person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at separate prices within the foregoing range.
- Amount of Shares Beneficially Owned Following Reported Transaction includes 104,414 unvested shares subject to restricted stock awards and 206,260 shares owned outright.
- There was no consideration given in exchange for the security.
Billionaire Hedge Funds
